Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 785 for functional healing after surgically fixed unilateral hip fracture
NL-OMON36359Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of romosozumab in hip fracture, Neck Of Femur Fracture and intertrochanteric fracture (4 arms), sponsored by Amgen. Primary endpoint: Functional healing by timed-up-and-go over Weeks 6 through 20. Started Feb 2011; status: active, not recruiting.
02
Drugs
romosozumab
03
Conditions
hip fractureNeck Of Femur Fractureintertrochanteric fracture
Beyond the preview
Go deeper on NL-OMON36359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36359.